Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Given “Buy” Rating at D. Boral Capital

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)‘s stock had its “buy” rating restated by stock analysts at D. Boral Capital in a research report issued on Friday,Benzinga reports. They currently have a $2.00 price target on the stock. D. Boral Capital’s target price would indicate a potential upside of 288.35% from the stock’s current price.

Separately, HC Wainwright upped their target price on Lineage Cell Therapeutics from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th.

Lineage Cell Therapeutics Trading Up 2.5 %

Lineage Cell Therapeutics stock opened at $0.52 on Friday. The company has a market cap of $113.52 million, a PE ratio of -4.29 and a beta of 1.16. Lineage Cell Therapeutics has a 1 year low of $0.48 and a 1 year high of $1.61.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC acquired a new position in shares of Lineage Cell Therapeutics in the 3rd quarter worth approximately $46,000. XTX Topco Ltd bought a new position in Lineage Cell Therapeutics during the 2nd quarter worth about $61,000. GSA Capital Partners LLP bought a new position in Lineage Cell Therapeutics in the third quarter valued at $84,000. Rhumbline Advisers grew its holdings in shares of Lineage Cell Therapeutics by 15.1% in the 2nd quarter. Rhumbline Advisers now owns 132,491 shares of the company’s stock valued at $132,000 after acquiring an additional 17,411 shares in the last quarter. Finally, Barclays PLC raised its stake in shares of Lineage Cell Therapeutics by 311.3% during the 3rd quarter. Barclays PLC now owns 211,300 shares of the company’s stock worth $192,000 after purchasing an additional 159,924 shares in the last quarter. Hedge funds and other institutional investors own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.